SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.470
+0.030 (0.87%)
Jun 2, 2026, 1:45 PM EDT - Market open
SAB Biotherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -0.4 | 13.27 | -34.11 | -42.19 | -18.74 | -17.14 |
Depreciation & Amortization | 3.06 | 3.08 | 4.79 | 3.75 | 3.29 | 1.65 |
Stock-Based Compensation | 10.06 | 5.21 | 2.94 | 2.42 | 2.67 | 2.31 |
Other Adjustments | -57.4 | -62.66 | -5.62 | 8.58 | -10.45 | 3.48 |
Change in Receivables | -1.53 | -0.89 | -0.05 | 5.56 | 2.45 | 12.56 |
Changes in Accounts Payable | 0.91 | 1.48 | 0.92 | -2.7 | -0.78 | -2.94 |
Changes in Accrued Expenses | -0.84 | 0.94 | -1.23 | -1.71 | -2.54 | 3.38 |
Changes in Other Operating Activities | -5.35 | -5.22 | -1.94 | 1.19 | 0.63 | -1.32 |
Operating Cash Flow | -51.25 | -44.78 | -34.29 | -25.12 | -23.46 | 1.99 |
Operating Cash Flow Growth | - | - | - | - | - | -80.14% |
Capital Expenditures | -1.92 | -0.93 | -0.34 | -0.2 | -2.17 | -10.94 |
Sale of Property, Plant & Equipment | 0 | 0 | - | 0.04 | 0.08 | - |
Purchases of Investments | -281.23 | -142.04 | -37.45 | - | - | - |
Proceeds from Sale of Investments | 91.12 | 21.26 | 25.82 | - | - | - |
Investing Cash Flow | -192.03 | -121.71 | -11.96 | -0.15 | -2.09 | -10.94 |
Long-Term Debt Issued | - | - | 0.52 | 0.77 | 1.24 | 2.84 |
Long-Term Debt Repaid | -0.14 | -0.28 | -1.29 | -1.03 | -2.26 | -1.09 |
Net Long-Term Debt Issued (Repaid) | -0.14 | -0.28 | -0.77 | -0.26 | -1.02 | 1.75 |
Issuance of Common Stock | 89.96 | 168.73 | 0.02 | 0.01 | 7.76 | 34.35 |
Repurchase of Common Stock | -0.01 | -0.01 | -0.02 | - | - | - |
Net Common Stock Issued (Repurchased) | 89.95 | 168.72 | -0 | 0.01 | 7.76 | 34.35 |
Issuance of Preferred Stock | - | - | - | 67.15 | - | - |
Net Preferred Stock Issued (Repurchased) | - | - | - | 67.15 | - | - |
Other Financing Activities | -0.15 | -0.14 | -0.39 | -0.13 | -5.68 | -0.2 |
Financing Cash Flow | 89.71 | 168.3 | -1.17 | 66.77 | 1.05 | 35.89 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | -0.24 | -0.21 | -0.24 | 0.02 | - | - |
Net Cash Flow | 14.88 | 1.6 | -47.67 | 41.52 | -24.5 | 26.93 |
Free Cash Flow | -53.17 | -45.71 | -34.63 | -25.32 | -25.63 | -8.96 |
FCF Margin | - | - | -2618.65% | -1130.71% | -107.20% | -14.71% |
Free Cash Flow Per Share | -0.72 | -0.75 | -3.74 | -4.59 | -5.89 | -3.28 |
Levered Free Cash Flow | -18.97 | 12.35 | -32.67 | -42.14 | -21.33 | -25.56 |
Unlevered Free Cash Flow | -62.32 | -49.6 | -40.7 | -37.76 | -30.44 | -23.56 |